Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors

References

• AKjaer. Molecular imaging of cancer using PET and SPECT. Adv Exp Med Biol 2006;587:277–84.
   PubMedGoogle Scholar
• SRHamilton, LAAaltonen. World Health Organization. WHO classification of tumors. Pathology and genetics. Tumours of the digestive system. Lyon: IARC; 2000.
   Google Scholar
• JCReubi, BWaser, JCSchaer, JALaissue. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836–46.
   PubMedGoogle Scholar
• TBinderup, UKnigge, AMellon Mogensen, CPalnaes Hansen, AKjaer. Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors. Neuroendocrinology 2008;87:223–32.
   PubMed Web of Science ®Google Scholar
• EPKrenning, DJKwekkeboom, WHBakker, WABreeman, PPKooij, HYOei, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716–31.
   PubMedGoogle Scholar
• KÖberg, UKnigge, DKwekkeboom, APerren. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23:vii124–30.
   PubMed Web of Science ®Google Scholar
• FJamar, RFiasse, NLeners, SPauwels. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med 1995;36:542–9.
   PubMed Web of Science ®Google Scholar
• MRaderer, AKurtaran, MLeimer, PAngelberger, BNiederle, HVierhapper, et al. Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998. J Clin Oncol 2000;18:1331–6.
   PubMed Web of Science ®Google Scholar
• KPKoopmans, ONNeels, IPKema, PHElsinga, TPLinks, EGde Vries, et al. Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. Crit Rev Oncol Hematol Elsevier 2009;71:199–213.
   PubMed Web of Science ®Google Scholar
• SLu, GGnanasegaran, JBuscombe, SNavalkissoor. Single photon emission computed tomography/computed tomography in the evaluation of neuroendocrine tumours: a review of the literature. Nucl Med Commun 2013;34:98–107.
   PubMed Web of Science ®Google Scholar
• EBombardieri, VAmbrosini, CAktolun, RPBaum, ABishof-Delaloye, SDel Vecchio, et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010;37:1441–8.
   PubMed Web of Science ®Google Scholar
• TBinderup, UKnigge, ALoft, JMortensen, APfeifer, BFederspiel, et al. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med Soc Nuc Med 2010;51:704–12.
   PubMed Web of Science ®Google Scholar
• AHubalewska-Dydejczyk, KFröss-Baron, RMikołajczak, HRMaecke, BHuszno, DPach, et al. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years’ experience. Eur J Nucl Med Mol Imaging 2006;33:1123–33.
   PubMed Web of Science ®Google Scholar
• MGabriel, PMuehllechner, CDecristoforo, EGuggenberg von, DKendler, RPrommegger, et al. 99mTc-EDDA/HYNIC-Tyr(3)-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors. Q J Nucl Med Mol Imaging 2005;49:237–44.
   PubMed Web of Science ®Google Scholar
• CBJohnbeck, UKnigge, AKjaer. Somatostatin receptor imaging with PET tracers of neuroendocrine tumors: current status and review of the literature. Future Oncol 2014;10:2259–77.
   PubMed Web of Science ®Google Scholar
• IKayani, JBBomanji, AGroves, GConway, SGacinovic, TWin, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer 2008;112:2447–55.
   PubMed Web of Science ®Google Scholar
• IKayani, BGConry, AMGroves, TWin, JDickson, MCaplin, et al. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med 2009;50:1927–32.
   PubMed Web of Science ®Google Scholar
• AHaug, CJAuernhammer, BWängler, RTiling, GSchmidt, BGöke, et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2009;36:765–70.
   PubMed Web of Science ®Google Scholar
• LKabasakal, EDemirci, MOcak, CDecristoforo, AAraman, YOzsoy, et al. Comparison of Ga-DOTATATE and Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2012;39:1271–7.
   PubMed Web of Science ®Google Scholar
• DWild, JBBomanji, PBenkert, HMaecke, PJEll, JCReubi, et al. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2013;54:364–72.
   PubMed Web of Science ®Google Scholar
• MHofmann, HMaecke, RBörner, EWeckesser, PSchöffski, LOei, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751–7.
   PubMedGoogle Scholar
• SKoukouraki, LGStrauss, VGeorgoulias, JSchuhmacher, UHaberkorn, NKarkavitsas, et al. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006;33:460–6.
   PubMed Web of Science ®Google Scholar
• IBuchmann, MHenze, SEngelbrecht, MEisenhut, ARunz, MSchäfer, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34:1617–26.
   PubMed Web of Science ®Google Scholar
• MGabriel, CDecristoforo, DKendler, GDobrozemsky, DHeute, CUprimny, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508–18.
   PubMed Web of Science ®Google Scholar
• DPutzer, MGabriel, BHenninger, DKendler, CUprimny, GDobrozemsky, et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009;50:1214–21.
   PubMed Web of Science ®Google Scholar
• AVersari, LCamellini, GCarlinfante, AFrasoldati, FNicoli, EGrassi, et al. Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clin Nucl Med 2010;35:321–8.
   PubMed Web of Science ®Google Scholar
• VAmbrosini, PTomassetti, PCastellucci, DCampana, GMontini, DRubello, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 2008;35:1431–8.
   PubMed Web of Science ®Google Scholar
• VAmbrosini, PCastellucci, DRubello, CNanni, AMusto, VAllegri, et al. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun 2009;30:281–6.
   PubMed Web of Science ®Google Scholar
• NNaswa, PSharma, AKumar, AHNazar, RKumar, SChumber, et al. Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. AJR Am J Roentgenol 2011;197:1221–8.
   PubMed Web of Science ®Google Scholar
• YKrausz, NFreedman, RRubinstein, ELavie, MOrevi, STshori, et al. 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ¹¹¹In-DTPA-octreotide (OctreoScan®). Mol Imaging Biol 2011;13:583–93.
   PubMed Web of Science ®Google Scholar
• NNaswa, PSharma, RSoundararajan, SKarunanithi, AHNazar, RKumar, et al. Diagnostic performance of somatostatin receptor PET/CT using 68Ga-DOTANOC in gastrinoma patients with negative or equivocal CT findings. Abdom Imaging 2013;38:552–60.
   PubMed Web of Science ®Google Scholar
• VAmbrosini, DCampana, PTomassetti, SFanti. Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Eur J Nucl Med Mol Imaging 2012;39:S52–60.
   PubMed Web of Science ®Google Scholar
• TDPoeppel, IBinse, SPetersenn, HLahner, MSchott, GAntoch, et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med 2011;52:1864–70.
   PubMed Web of Science ®Google Scholar
• EDemirci, MOcak, LKabasakal, AAraman, YOzsoy, BKanmaz. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results. Nucl Med Commun 2013;34:727–32.
   PubMed Web of Science ®Google Scholar
• DPutzer, AKroiss, DWaitz, MGabriel, TTraub-Weidinger, CUprimny, et al. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide. Eur J Nucl Med Mol Imaging 2013;40:364–72.
   PubMed Web of Science ®Google Scholar
• APfeifer, UKnigge, JMortensen, POturai, AKBerthelsen, ALoft, et al. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. J Nucl Med 2012;53:1207–15.
   PubMed Web of Science ®Google Scholar
• APfeifer, CBJohnbeck, UKnigge, JMortensen, POturai, ALoft, et al. Clinical PET imaging of neuroendocrine tumors using 64Cu-DOTA-Tyr3-octreotate. J Nucl Med 2013;54:1854.
   Google Scholar
• CJAnderson, FDehdashti, PDCutler, SWSchwarz, RLaforest, LABass, et al. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 2001;42:213–21.
   PubMed Web of Science ®Google Scholar
• HOrlefors, ASundin, HAhlström, PBjurling, MBergström, ALilja, et al. Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors. J Clin Oncol 1998;16:2534–41.
   PubMed Web of Science ®Google Scholar
• HOrlefors, ASundin, UGarske, CJuhlin, KOberg, BSkogseid, et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005;90:3392–400.
   PubMed Web of Science ®Google Scholar
• KPKoopmans, OCNeels, IPKema, PHElsinga, WJSluiter, KVanghillewe, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 2008;26:1489–95.
   PubMed Web of Science ®Google Scholar
• DPutzer, MGabriel, DKendler, BHenninger, MKnoflach, AKroiss, et al. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q J Nucl Med Mol Imaging 2010;54:68–75.
   PubMed Web of Science ®Google Scholar
• DWild, HMäcke, EChrist, BGloor, JCReubi. Glucagonlike peptide 1-receptor scans to localize occult insulinomas. N Eng J Med 2008;359:766–8.
   PubMed Web of Science ®Google Scholar
• DWild, EChrist, MECaplin, TRKurzawinski, FForrer, MBrändle, et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med 2011;52:1073–8.
   PubMed Web of Science ®Google Scholar
• RKSelvaraju, IVelikyan, LJohansson, ZWu, ITodorov, JShively, et al. In vivo imaging of the glucagon-like peptide 1 receptor in the pancreas with 68Ga-labeled DO3A-exendin-4. J Nucl Med 2013;54:1458–63.
   PubMed Web of Science ®Google Scholar
• OEriksson, IVelikyan, RKSelvaraju, FKandeel, LJohansson, GAntoni, et al. Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report. J Clin Endocrinol Metab 2014;99:1519–24.
   PubMed Web of Science ®Google Scholar
• TBinderup, UKnigge, ALoft, BFederspiel, AKjaer. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010;16:978–85.
   PubMed Web of Science ®Google Scholar
• DJKwekkeboom, WWde Herder, BLKam, CHvan Eijck, Mvan Essen, PPKooij, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124–30.
   PubMed Web of Science ®Google Scholar
• AImhof, PBrunner, NMarincek, MBriel, CSchindler, HRasch, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011;29:2416–23.
   PubMed Web of Science ®Google Scholar
• LBodei, MCremonesi, CMGrana, NFazio, SIodice, SMBaio, et al. Peptide receptor radionuclide therapy with ¹Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging 2011;38:2125–35.
   PubMed Web of Science ®Google Scholar
• AKPfeifer, TGregersen, HGrønbæk, CPHansen, JMüller-Brand, KHerskind Bruun, et al. Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Neuroendocrinology 2011;93:189–96.
   PubMed Web of Science ®Google Scholar
• RValkema, Mde Jong, WHBakker, WABreeman, PPKooij, PJLugtenburg, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2002;32:110–22.
   PubMed Web of Science ®Google Scholar
• LBAnthony, EAWoltering, GDEspenan, MDCronin, TJMaloney, KEMcCarthy. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002;32:123–32.
   PubMed Web of Science ®Google Scholar
• Mde Jong, WABreeman, RValkema, BFBernard, EPKrenning. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med 2005;46:13S–7S.
   PubMed Web of Science ®Google Scholar
• LVillard, ARomer, NMarincek, PBrunner, MTKoller, CSchindler, et al. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol 2012;30:1100–6.
   PubMed Web of Science ®Google Scholar
• RValkema, SPauwels, LKKvols, RBarone, FJamar, WHBakker. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006;36:147–56.
   PubMed Web of Science ®Google Scholar
• DLBushnellJr, TMO’Dorisio, MSO’Dorisio, YMenda, RJHicks, Evan Cutsem, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010;28:1652–9.
   PubMed Web of Science ®Google Scholar
• LBodei, MKidd, GPaganelli, CMGrana, IDrozdov, MCremonesi, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging 2015;42:5–19.
   PubMed Web of Science ®Google Scholar
• ETJanson, HSorbye, SWelin, BFederspiel, HGrønbæk, PHellman, et al. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol 2014;53:1284–97.
   PubMed Web of Science ®Google Scholar
• UKnigge, CPHansen. Surgery for GEP-NETs. Best Pract Res Clin Gastroenterol 2012;26:819–31.
   PubMed Web of Science ®Google Scholar